Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer - Test2 - elhamkhani - TriplyDB

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

http://www.wikidata.org/entity/Q29615679

about

Agility in adversity: Vaccines on Demand Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment Radiotherapy combination opportunities leveraging immunity for the next oncology practice The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics DNA damage, tumor mutational load and their impact on immune responses against cancer Towards tumor immunodiagnostics Neoantigen-based cancer immunotherapy Targeted therapies and immunotherapy in non-small-cell lung cancer The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer Aptamers: A Feasible Technology in Cancer Immunotherapy Tackling ALK in non-small cell lung cancer: the role of novel inhibitors Recent advances in molecular genetics of melanoma progression: implications for diagnosis and treatment New targeted treatments for non-small-cell lung cancer - role of nivolumab PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications.The role of pembrolizumab in the treatment of advanced non-small cell lung cancer Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer Checkpoint Inhibitors and Their Application in Breast Cancer Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints The steady progress of targeted therapies, promising advances for lung cancer Tumor-intrinsic oncogene pathways mediating immune avoidance Prime time for immune-checkpoint targeted therapy at ASCO 2015 Gene aberrations for precision medicine against lung adenocarcinoma Immunotherapy for lung cancer Cancer immunotherapy: the beginning of the end of cancer?Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer Cellular and molecular biology of small cell lung cancer: an overview Advances in immunotherapy for melanoma PD-1/PD-L1 blockade in cancer treatment: perspectives and issues Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity Novel technologies and emerging biomarkers for personalized cancer immunotherapy Predictors of clinical response to immunotherapy with or without radiotherapy Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies New strategies in immunotherapy for non-small cell lung cancer

P2860

Q26252583-513D0169-AD2E-4459-90F3-B5E19B3F13A7 Q26738359-47E3C2F3-B8AC-4851-8902-CAE37C7CCDD9 Q26738443-D7C04AAF-35AD-412C-B026-6AD05C84EDCB Q26738677-AB83BEF0-A98C-407B-A11D-6A9006628F49 Q26738685-56035C47-90E4-40F1-A2F5-23A28B6AD943 Q26738691-18DC8E10-DF34-4E56-BA20-F07BD132B53A Q26738693-321BBE62-5DBA-4D48-80BD-EBADB241E0EF Q26738986-69461DFC-1CD9-4BCD-93AE-7C20C1F492E2 Q26740280-E9BF8158-A4A5-4E91-BEF9-059596F7CABC Q26740288-917BBAE9-1627-45E9-85EB-0326EF693922 Q26740303-F5431FAE-65FB-4893-8EF6-772ECB13B9B2 Q26740329-9846C8EB-1ADD-48BD-9345-4E4D334491A8 Q26740631-B941853F-4A42-4A89-BC90-93E805BF03B3 Q26740988-42B4DA79-CE37-4C28-8827-D41CD206658A Q26741101-EE047FF1-B9D9-414E-9EA3-DC95BCB889F8 Q26741529-713F1DFA-E654-454E-963E-D12460707AAF Q26744076-F50FC545-0686-4E5D-BEA2-EBC1172006A8 Q26744758-26700A10-785B-412B-A6B2-3F9F225ABF78 Q26745442-6ACCBD0C-5DD1-472A-90AE-36276258F0C7 Q26745516-822E0F9D-2525-4665-A064-9C915D7AF8D1 Q26745590-26D6BC94-BDE5-49C3-83C6-20707C6F9F61 Q26745842-02CC94E0-2C19-4E0F-AC8A-B13B671A6611 Q26746895-39C3FA41-1DBA-4A0D-B984-CC0CA169F255 Q26747707-0E761516-F49B-43D6-8C54-77A4237ED237 Q26747711-6E86849C-EF49-4ED5-851C-4ADBE4E5CF04 Q26749348-9AEDDCE1-6AD1-4D91-9D89-468B5B05C64F Q26751254-45002E5A-26D0-4DE7-8120-A5B2593028A5 Q26752277-97A66CAA-C7A2-432D-80C5-440ECE0FEA8C Q26765060-FFB4FC20-E542-4BF9-9DED-590F00E94203 Q26766285-7216947A-8C0A-45EF-86C6-3CA58FDC2E82 Q26767029-B880FA67-D6F4-4307-A1ED-3C7E33FBDEAD Q26768558-9F50211B-F995-45B8-A739-7CC56B76583F Q26768641-9CB45F53-DF22-40AC-8EAB-B8F22ABFB7C8 Q26769044-D2269F25-45B9-42D2-9B94-EB3AC90A032F Q26769734-BB58A461-27BA-4788-8244-58E864A65AEE Q26769744-C361088C-14C2-48EF-8F4D-8878C34775D4 Q26770780-FD5CE6FB-4C64-4A8E-B435-DF2BC403C770 Q26771870-ABC99B64-6BF2-4051-A9F7-0CFCF5D7C7A2 Q26775034-B8C3D5BF-AF5C-4CA5-948F-192A93B90FB5 Q26775385-9578A9C9-6BAB-4978-86DB-80BA2C719022

P2860

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

http://www.wikidata.org/entity/Q29615679

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Cancer immunology. Mutational ...... in non-small cell lung cancer

@ast

Cancer immunology. Mutational ...... in non-small cell lung cancer

@en

type

label

Cancer immunology. Mutational ...... in non-small cell lung cancer

@ast

Cancer immunology. Mutational ...... in non-small cell lung cancer

@en

prefLabel

Cancer immunology. Mutational ...... in non-small cell lung cancer

@ast

Cancer immunology. Mutational ...... in non-small cell lung cancer

@en

P1433

Q29615679-B060E402-7CAA-4658-9765-A96C8AF56494

P1476

Q29615679-3EE8331A-7B0D-4EAF-AAE5-3FC7EB393385

P2093

Q29615679-09D4B47A-D855-440E-A6F7-426D82D23B4A

Q29615679-215EB7A3-1EC0-438A-84E9-EF89F9300487

Q29615679-36187575-94D5-4A58-BD0E-E9FE8DB5CCA8

Q29615679-3983DD13-4D36-4F19-AB75-C2C058FC2E1E

Q29615679-4E9A02F5-81BF-4B44-852E-E069D3B352B6

Q29615679-6028DA8B-5811-491F-A3F0-0CF5A87647AD

Q29615679-7BA6D474-3FB7-4ABF-BE45-DB18FFB38901

Q29615679-8241EE8D-F255-4E84-8C2E-910D5D5CA27F

Q29615679-92BA21EB-4FC6-4F72-9356-8E16DD4C6799

Q29615679-94DF5C53-6E63-42E6-A86A-4F8B68B274A2

P2860

Q29615679-07BDEA51-154E-45D4-87BB-0071F13A6A23

Q29615679-0D55B86C-12DB-4211-8181-26C606C88288

Q29615679-0FB996A2-951B-434A-8C29-FAAB219555F9

Q29615679-11812DD5-E20F-4A70-8965-7E20778185E0

Q29615679-13804803-205B-468D-B49F-604711FC3018

Q29615679-151D1324-B8E2-4C1C-BC08-6CFB7BF76BE5

Q29615679-171C88E5-66C9-4642-BEA7-B9E1604EB04E

Q29615679-19905AC8-037F-4F4E-BBAE-15A4B53BC41F

Q29615679-1B98EE25-BD8D-4F9F-9902-F6A92096F053

Q29615679-1C5203F4-FDA7-46AE-83C3-AABFA020B1F2

P304

Q29615679-464B1F23-DB7E-46DE-BF0D-DED07D172AA2

P31

Q29615679-C7F178E2-C09B-4905-9730-26DACC7C96E9

P3181

Q29615679-10171472-CF43-41C4-BAE9-BABB005C7222

P356

Q29615679-8118BADA-DCEA-4E5B-BA7C-F1ED60386048

P407

Q29615679-71838BBE-921A-4A41-A8D0-B508329C0D2D

P433

Q29615679-AE2089C7-4F84-492C-9D58-13E17A9D2B2E

P478

Q29615679-854D4F88-0393-4D29-A7BF-94F339C70CB8

P50

Q29615679-043D5D6B-5DDD-4D3A-AA7A-C6D05D5939E9

Q29615679-33E520ED-9923-46BF-872F-AC9D314F133A

Q29615679-3AC4D3EC-F56A-469B-999A-C9F144C05D22

Q29615679-5A59B3B2-7482-466C-B92C-889E1C7F9571

Q29615679-60A35EEC-C94A-419F-BE64-DFC4237CAC5D

P5008

Q29615679-C00BCF1D-4B24-4196-893E-AB2D3BA7F594

P577

Q29615679-20D14682-3FE3-4F2B-B151-D48766399AB1

P5875

Q29615679-F7A9F889-07C7-4B91-B6BC-7D1D3E47B58F

P698

Q29615679-B14C6327-C301-432A-9CC7-C023A05EC58F

P921

Q29615679-c2b7407f-424b-a472-a8a9-438864ec666f

P932

Q29615679-A1DC295F-0148-46CD-A5FC-509D9DDA5D7C

P3181

P356

SCIENCE.AAA1348

P1433

P1476

Cancer immunology. Mutational ...... in non-small cell lung cancer

@en

P2093

Alexandra Snyder

http://www.w3.org/2001/XMLSchema#string

Andre L Moreira

http://www.w3.org/2001/XMLSchema#string

Billel Gasmi

http://www.w3.org/2001/XMLSchema#string

Cameron Bruggeman

http://www.w3.org/2001/XMLSchema#string

Chris Sander

http://www.w3.org/2001/XMLSchema#string

Edward B Garon

http://www.w3.org/2001/XMLSchema#string

Fawzia Ibrahim

http://www.w3.org/2001/XMLSchema#string

Jedd D Wolchok

http://www.w3.org/2001/XMLSchema#string

Jianda Yuan

http://www.w3.org/2001/XMLSchema#string

Matthew D Hellmann

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer genome landscapes

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers

Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas

VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Fast and accurate short read alignment with Burrows-Wheeler transform

Beyond DNA repair: DNA-PK function in cancer

Reliable prediction of T-cell epitopes using neural networks with novel sequence representations

Nivolumab plus ipilimumab in advanced melanoma.

P304

124-128

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

92012

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCIENCE.AAA1348

http://www.w3.org/2001/XMLSchema#string

P407

P433

6230

http://www.w3.org/2001/XMLSchema#string

P478

348

http://www.w3.org/2001/XMLSchema#string

P50

Martin L Miller

Roberta Zappasodi

Jonathan J Havel

Ton N Schumacher

P5008

P577

2015-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273465425

http://www.w3.org/2001/XMLSchema#string

P698

25765070

http://www.w3.org/2001/XMLSchema#string

P921

non-small-cell lung carcinoma

P932

4993154

http://www.w3.org/2001/XMLSchema#string